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What is already known about this topic:    
1. Innovation and technological development have commonalities across all 
disciplines in terms of process, evaluation, and incorporation into use. 
2. Many technologies have evolved through traditional methods such as research 
grant funding, individual and multicenter trials, followed by eventual 
introduction into common practice. Others have been significantly sped up by 
industrial resources and drive. 
What this study adds: 
1. The development of basic new concepts and procedures will very like continue to 
reside the academic environment. 
2. As the pace of technological development has rapidly accelerated and academic 
support for such work has significantly diminished, corporate involvement, 
sponsorship, and partnering have become much more common and, particularly for 
laboratory techniques, are necessary to achieve progress at a rapid pace. 
3. There is a balance that needs to be respected between the benefits and constraints 
of such industrial involvement that will require compromise on both sides to achieve 
an optimal environment. 
 
INTRODUCTION   (MARK EVANS) 
 
 The process of innovation has its own set of norms that can be applied across many 
disciplines regardless of whether the subject is a surgical procedure, imaging equipment, 
laboratory testing, or a hundred others1,2. In the United States, for example, the Federal 
government has agencies such as the Office of Health Research, Statistics, and Technology 
under which are the National Center for Health Statistics, National Center for Human 
Services Research, and the National Center for Health Care Technology (NCHCT). In the 
1980’s I was a Special Advisor to the Director of the NCHCT (initially focusing on AFP 
screening) whose mission has morphed into the Agency for Health Care Research and 
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Quality and focuses on the evaluation of new technologies and how they should be 
incorporated into medical practice. These agencies were created to provide the foundation 
upon which to understand problems and provide baselines against which to study new 
approaches. International Societies such as Health Technology Assessment International 
have likewise provided a framework for understanding the similarities and differences 
among seemingly disparate disciplines3. For example, a university or hospital can have a 
department of obstetrics and gynecology, which might have divisions of general obstetrics, 
general gynecology, maternal fetal medicine, reproductive endocrinology, and gynecologic 
oncology.  A cancer center could have divisions of pediatric oncology, hematology/oncology, 
gynecologic oncology, etc.  The two approaches to gynecologic oncology in this example 
start from somewhat different basic perspectives of mission and vision, but are adaptable to 
the specific technology and purposes.   
 There are two distinct phases of technology innovation in medicine. First, there is a 
phase of “development” in which a small number of investigators – traditionally but not 
necessarily at academic medical centers – have an idea, establish the concept for its use, 
test, maybe patent, publish, present, and create a demand for the technology/service.  
Then, as the demand grows, and the originators can no longer handle the demand, there is a 
phase of “diffusion.” The technology moves out from the primary center to many other 
providers and sites.  As the volume grows rapidly as inexperienced providers get in the 
game, but complication rates skyrocket 1,2. Eventually, the level of performance improves as 
the concept is absorbed into practice, and there is a learning curve for the new providers.   
While the above is most obvious for surgical procedures, it also applies to laboratory 
ones. The more subjective the process, the more that the pitfalls of diffusion apply. Many of 
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the new genetic laboratory technologies begin as laboratory developed tests (LDTs) with 
jury-rigged systems modified from other methods before there is sufficient standardization 
to have “kits,” with US Food and Drug Administration (FDA) or Conformité Européenne (CE) 
clearance, which can have much of their quality control built in before the laboratory ever 
attempts to use them.     
The debate question was: Industry drives innovation in research and clinical 
application of genetic prenatal diagnosis and screening.  Speaking for the proposition was 
Tom Musci M.D. a maternal fetal medicine physician of Ariosa Diagnostics, and against was 
Joris Robert Vermeesh Ph.D.  a molecular cytogeneticist of the Catholic University of Leuven.  
The moderator was Mark I. Evans, M.D. an obstetrician/gynecologist and medical geneticist 
from the Fetal Medicine Foundation of American and Mt. Sinai School of Medicine. 
 
FOR (MARK EVANS*) 
 (Footnote:  Written by Dr. Evans using Dr. Musci’s speech and slides with his 
permission as basis).  
Historically, students were always taught that one develops a rigorously based research 
hypothesis and then does experiments to prove or disprove the specific question. “Fishing 
expeditions” of just throwing stuff up against the wall and seeing what happens were 
disparaged as poor science.  A disproportionate amount of advancements in medicine now 
come from applying technological advances from engineering, chemistry, optics, and other 
disciplines at a distance from genetics and other specialties of medicine.  In such 
environments, applying a technology to multiple scenarios that are seemingly unrelated and 
seeing what it can do in any field is considered just as reasonable as pursuing physiologically 
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based hypotheses.1,2 All academic grant funding is now very difficult to obtain, but for non-
physiologic research technology tests, it is even more so.  Since 1997, NICHD has seen the 
success rate of grant applications fall from 24.6% down to 11.5% (Table 1)4. It is even lower 
for investigator-initiated applications. Furthermore, NICHD overall funding and success of 
obtaining it are much lower than several other institutes such as General Medical Sciences, 
Heart, Lung, and blood, and neurologic disorders and stroke (Table 2)5. Adjusting for 
inflation has only made the support statistics even worse.  
As a result of the above as well as general cut-backs in Medicare and Medicaid 
funding, the administrative dollars previously available to support academic research and 
investigators have dramatically shrunk. “Protected time” is now more myth than reality.  
Without access to new sources of research support, the academic triad of patient care, 
teaching, and research would be left with only the clinical practice leg because it pays the 
bills and balances the budget quarter by quarter. Long term strategic planning has largely 
disappeared.  
 There are numerous technologies that, were it not for considerable corporate 
funding the science, would not be available. One of the first genetic technologies largely 
developed by industry in the 1980’s and 90’s was fluorescent in situ hybridization for 
molecular identification of selected chromosome abnormalities 6. There was initially 
considerable resistance among some circles to accepting at face value research from 
companies as compared to academic centers, but this got better over a period of some 
years as the data met all the same standards that would be expected from academic 
centers. 
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 The most obvious industrial involvement in prenatal diagnosis has been the 
development of cell free fetal DNA (cffDNA) testing for non-invasive prenatal screening 
(NIPS) 7,8. Over a decade two multicenter NICHD funded projects were not able to bring the 
analysis of fetal cells in maternal blood into clinical practice 9. Following their completion, a 
number of companies entered into the field – often including investigators previously part 
of the NICHD consortium.  When the science shifted from fetal cells to cell free fetal DNA 
and RNA, large amounts of applied research funding were obtained to capitalize and exploit 
new technology.  No NIH funded mechanism could have worked with anywhere the speed 
and extent of the private sector enterprise.  As a result, cffDNA has assumed a primary 
position in Down syndrome screening that would not have otherwise been possible 10. 
The other major current technology that had enormous corporate involvement was 
array comparative genomic hybridization (aCGH) or chromosomal microarrays 11,12. Much of 
the developmental work was done by industry including a number of significant 
publications.  However, it was only through the NICHD collaborative study, that there was 
general acceptance of the much higher than originally expected incidence of abnormal fetal 
copy number variants (CNVs).  This study was only possible, however, by the collaboration 
of the NIH with multiple companies performing microarrays who agreed to provide services, 
share data, and other ordinarily proprietary resources in order to make it work11,12.  
Similarly, pre-implantation diagnosis and screening would not have been possible 
without industry driven science 13. In fact, in the United States, there was a federal funding 
moratorium for all IVF related research that forced the entire IVF enterprise to be created 
off- shore. This was because in the late 1970’s and 80’s there wasn’t a reservoir of venture 
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capital that could be applied to research and development.  Thus, without private support, 
such work would have been completely impossible.  
Supporters of the academic model of “how it should be done” do not have a real 
answer for how they can survive without corporate and venture capital to support their 
research efforts. The Faustian bargain is that more and more industrial supported research 
and development is focused on application and product development rather than basic 
research to create new areas of opportunity.  
AGAINST (JORIS VERMEESCH) 
 
All key breakthroughs that have shaped prenatal and preimplantation genetic diagnosis over 
the last 50 years have been established in academia (Table 3).  To exemplify the mechanism 
of this innovation process, I will focus on the two major revolutions that have taken place in 
prenatal genetic testing during the last 10 years, and for which I have had the privilege to be 
closely involved. 
A first revolution was the development and implementation of arrays for prenatal genetic 
diagnosis.  Array CGH, also termed molecular karyotyping or chromosomal microarrays, 
have largely replaced conventional karyotyping and this (r)evolution has occurred over the 
last 20 years.  What were the innovations and who triggered them? At the end of the 
1990’s, FISH was well established.  In the FISH procedure a single DNA fragment is 
fluorescently labeled and hybridized to chromosomes.  Only copy number changes in that 
clone can be detected.   Dan Pinkel and Peter Lichter reasoned that if FISH probes would be 
spotted on a glass slide and genomic DNA hybridized, a series of genomic loci could be 
interrogated for copy number changes 14. It took subsequently another 5 years, before 
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academic scientists could optimize the method to work systematically and enable the 
detection of simple duplications and deletions.  Under the guidance of Nigel Carter from the 
Sanger institute, a working group and a ring test was instigated and samples and procedures 
were exchanged 15. Most importantly, the Sanger Institute shared the cloned human 
genome amongst all scientists. This methodology subsequently confirmed the hypothesis 
that a significant number of birth defects are caused by intrachromosomal copy number 
changes 16,17. Subsequently, it was a small step from the use of chromosomal microarrays 
for the detection CNVs as the cause of constitutional developmental disorders to prenatal 
disorders.  Following this proof of concept, translational academic researchers gathered to 
establish the first clinical studies, establish guidelines, and subsequently implement them 
into clinical care.  In Belgium, the academic laboratories united to establish societally 
accepted approaches to deal with CNVs 18.  Knowledge of CNVs is in the public space, 
because scientific laboratories have shared this information publicly.   Despite claims to the 
contrary, industry was not involved in making this transition from conventional karyotyping 
to chromosomal microarrays. Industry, starting 2006-2007, stepped in to mass produce 
arrays. 
 
A second major revolution has been the development of noninvasive prenatal screening 
(NIPS) with cffDNA.  Again, the original discovery that free floating plasma DNA contained 
placental fragments in pregnant women was made in an academic setting.  Dennis Lo, first 
in Oxford and later in Hong Kong, played a key role in the initial discovery and 
implementation 7,8. Subsequently, different prenatal screening strategies have been 
developed.  All of them have been in the academic environment.   The holy grail of NIPS was 
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the potential to discriminate fetal aneuploidies.  Again, the main method was developed in 
an academic setting.  The proof of concept that the fetal genome sequence can be 
reconstituted from the free floating DNA was made in academia.   The key patents were 
mainly filed by academic laboratories. 
The data fraud that temporarily derailed the enterprise was in the industry 
environment, fueled by a corporate rush to commercialize a product without any refereed 
publications and reasonable vetting19.  It is highly likely that such would not have happened 
in an academic environment. There were multiple complaints at national and international 
meetings by highly respected “key opinion leaders” in and out of academia, that this was 
inappropriate. Such did not sway the company. However, it should be stated clearly that the 
fraud was actually discovered by internal, corporate academically trained professionals who 
with ethics and courage made it public and fixed it. 
 
Rather than asking the question whether industry drives innovation, we have to ask 
the question why industry does not drive innovation?  Leaders in research are artists who 
create visions and possibilities. Aberrant or unexpected results are not discarded but rather 
become the source for surprise, hypothesis building and subsequently, mainly through 
serendipity, new discoveries.   Researchers see future potential in their innovation.  At the 
first moment, however, techniques, methods, and insight do not yet exist beyond the 
researcher’s mind.  Subsequently, the method has to be proven to work.   Grants are 
sought, which are only successful if there has already been some proof of concept.  Hence, a 
researcher has to provide a proof of concept. Particularly for radically new concepts, often 
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even the leading colleagues do not recognize the potential, or do not believe the method 
can work. 
Industry, in contrast, is by definition risk averse.  Aberrant results are a nuisance and 
have to be avoided.  To demonstrate this view, I turn to cffDNA performed by whole 
genome shotgun sequencing in commercial entities. In the first three years, those 
companies have reported to have performed over 1 million tests.  Yet as of early 2015, only 
trisomies 13, 18,21 , and sex chromosome aneuploidies were  clinically reported back 
routinely to patients.   We performed 2000 tests and presymptomatically identified a non-
Hodgkin lymphoma in a pregnant woman 20.  Since then, we have tested over 10,000 
pregnant women and have identified 5 abnormal genome wide profiles consistent with the 
presence of different presymptomatic cancers 21.  Soon after these reports, maternal 
malignancies were detected in a joint commercial and academic driven project 22. 
Extrapolated to the million patients performed in industry, 500 pregnant women with 
cancer did not obtain a diagnosis of cancer despite the data being present.  In addition, we 
are reporting aneuploidies beyond trisomies 13, 18, and 21.  It is becoming clear that those 
aneuploidies affect embryonic development and that reporting those may improve 
pregnancy management.  Those observations were made in the academic laboratories, not 
in the industrial scale NIPS testing laboratories 21,23. 
Industry actually has a propensity to hamper rather than to drive innovation!  The 
majority of the patents were granted to university researchers and subsequently licensed to 
industry.  Industrial players try to maximize their market share and block competition as 
much as possible.  In addition, they try to extend the life span of their patents.  In the NIPS 
world, we are all well aware of the dominant patent portfolio in some industrial hands. The 
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bigger companies can threaten the development of new methods and protocols by suing 
new players.  Smaller laboratories or companies cannot pay the litigation costs and refrain 
from developments.  If such a situation emerges, waiting until the patents expire or new 
breakthroughs which change the landscape is common. 
Nevertheless, there is an important role for industry:  First, a method/technique can 
be mass produced.  This is not the role of academics nor of hospital laboratories; between 
2002 and 2009 my laboratory printed over 10,000 BAC arrays.  That was a huge effort, but 
clearly only sufficient to help 10,000 individuals and not the millions that are served today. 
Mass production of arrays has reduced the prices, improved quality, and increased the 
resolution.  Second, academic methods/software/techniques usually provide proof-of-
concept and are not meant to be brought into less academic environments.  Industry can 
build the refinements required for specific end-users.  Third, industry operates at a global 
scale and thus reaches a broader audience.  The marketing machineries enable fast and 
global access to concepts that were developed locally.  Finally, the large investment needed 
for large scale proof-of-concept, clinical validity,   and utility studies which can be more 
easily obtained via industrial funding mechanisms (for an overview of large scale industry 
driven NIPT studies please refer to references 24,25). 
Cooperation between academics and industry is obviously needed.  Both parties 
have to recognize each other’s merits and limitations.  In order to retain long term thrust in 
the health care machinery it seems to me important that academic independency is 
warranted.  Academic researchers and medics have to be able to voice opposing views and 
act independent of industry.  A too high dependence on industrial funding has the risk that 
this independence would be (perceived) not to exist. 
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CONCLUSIONS (MARK EVANS) 
 
 There is no doubt that each of the perspectives on whether industry drives 
innovation has a lot of data to support their respective positions. The reality is that both 
academia and industry want advancement in science – whether it be for knowledge sake, 
per se, better patient care and outcomes, academic development and promotion, or 
financial gain.  There is no clearer example than the commercial rush to extend cffDNA to 
the low risk population with the abandonment of diagnostic procedures in a population for 
which the incidence of microarray detectable anomalies is actually 10 times that of Down 
syndrome. 10,26  The shift away from diagnostic procedures will actually cost more and find 
less as the increase in DS detection is much less than the potential additional findings from 
microarrays currently possible only with CVS or amniocentesis. 10,12,18,26 
The question as framed for the debate is overly ambiguous and broad. One thing 
that crystalized during the actual debate and subsequent audience discussion seemed to be 
the understanding and acceptance by the audience that, as a very generic conclusion, basic 
new concepts and the groundwork needed before clinical application would mostly 
continue to come from academia.  However, once there was potential for 
commercialization, industry would be the more efficient driver and source of funding to 
bring the new technique over the finish line into routine care.  As such, the audience vote 
was essentially a tie. It was only the perceived framing of the question that determined 
which part of innovation and development seemed more important to the audience 
members. 
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TABLES 
 
Table 1 
 
NICHD GRANT FUNDING 1997 – 2015 
 
Year 
Grant 
proposals Awarded Total costs Average award 
Success 
Rate  
1997 1438 353  $     99,309,333.00  $281,329.56  24.6% 
2000 1541 449  $  136,172,848.00  
          
$303,280.29  29.1% 
2003 1913 508  $  148,957,079.00  
            
$293,222.60  26.6% 
2006 2789 423  $  141,259,518.00  
            
$333,946.85  15.2% 
2009 2784 416  $  140,940,875.00  
            
$338,800.18  14.9% 
2012 3554 443  $  170,466,344.00  
            
$384,799.87  12.5% 
2015 3439 397  $  149,468,763.00  
            
$376,495.62  11.5% 
 
https://report.nih.gov/success_rates/Success_ByIC_Details.cfm  accessed 9 21 16 
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Table 2 
 
NIH GRANT FUNDING BY INSTITUTE   2015 
Institute* 
Grant 
proposals Awarded Total costs Average award Success Rate 
NIAID 5932 1272  $  577,320,121.00             $453,868.02  21.4% 
NCI 9513 1236  $  508,125,718.00              $411,104.95  13.0% 
NHLBI 4233 928  $  497,923,174.00              $536,555.14  21.9% 
NIGMS 3626 1074  $  404,894,040.00              $376,996.31  29.6% 
NINDS 3992 819  $  310,868,609.00              $379,570.95  20.5% 
NICHD 3439 397  $  149,468,763.00              $376,495.62  11.5% 
NHGRI 320 60  $     46,248,195.00              $770,803.25  18.8% 
 
https://report.nih.gov/success_rates/Success_ByIC_Details.cfm  accessed 9 21 16 
 
 
* 
NIAID:   National Institute of Allergy and Infectious Disease 
NCI:  National Cancer Institute 
NHLBI:   National Institute of Heart, Lung, and Blood Institute 
NIGMS: National Institute of General Medical Sciences 
NINDS:  National Institute of Neurological Disorders and Stroke 
NICHD:  National Institute of Child Health and Human Development 
NHGRI:  National Human Genome Research Institute 
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Table 3    
PRENATAL GENETIC TESTING INNOVATIONS PIONEERED IN 
ACADEMIA 
Year Innovation 
1966 Karyotype following amniotic fluid sampling 27 
1967 First prenatal karyotype of chromosomal abnormality28 
1970-1975 Improvements in karyotyping result in higher resolution.  
1994 Fluorescent in situ hybridization (FISH) 2922 
1994 Quantitative-fluorescent PCR (qfPCR) enable aneuploidy detection in interphase nuclei 
30 
1997 Discovery of cell free fetal DNA in maternal plasma8 
1998 Non-invasive rhesus testing 31 
2002 Non-invasive detection of a monogenic disease 32 
2002 Multiplex ligation-dependent probe amplification (MLPA)33 
2005 Array-comparative genomic hybridization (aCGH) for detection of fetal DNA copy 
number imbalances 34 
2008 Non-invasive fetal aneuploidy screening 35,36 
2010 Fetal genome reconstitution from cfDNA analysis using parental genotype information 
37 
2015 Prenatal exome sequencing 38 
 
